πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors β€” phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β€” searchable for business development and competitive intelligence.

4,589 results for β€œPharma” Clear

  1. Sapropterin Dihydrochloride

    BioMarin Pharmaceutical Australia Pty Ltd

    Endothelial Dysfunction

    phase 2 small molecule completed

    1 trial

  2. Sapropterin Dihydrochloride

    BioMarin Pharmaceutical Australia Pty Ltd

    Intermittent Claudication

    phase 2 small molecule completed

    1 trial

  3. Saruparib, ZYTIGA 500 mg film-coated tablets, Erleada 60 mg film-coated tablets, Saruparib, Xtandi - 40 mg soft capsules, Prednisone Mylan Pharma 5 mg compresse, NUBEQA 300 mg film-coated tablets, Saruparib

    AstraZeneca AB

    Metastatic Prostate Cancer

    phase 2 small molecule active

    1 trial

  4. Sativex

    Jazz Pharmaceuticals Ireland Limited

    Cancer

    phase 2 small molecule completed

    2 trials

  5. Scemblix 20 mg film-coated tablets, Tasigna 200 mg hard capsules, Scemblix 40 mg film-coated tablets, Tasigna 150 mg hard capsules

    Novartis Pharmaceuticals

    Chronic myeloid leukemia

    phase 2 small molecule active

    1 trial

  6. Scemblix 40 mg film-coated tablets

    Novartis Pharmaceuticals

    CML-CP or CML-AP patients with T315I mutation

    phase 2 small molecule active

    1 trial

  7. Scemblix 40 mg film-coated tablets, Scemblix 40 mg film-coated tablets, Scemblix 20 mg film-coated tablets, Scemblix 40 mg film-coated tablets, NILOTINIB, NILOTINIB, Scemblix 20 mg film-coated tablets, IMATINIB, IMATINIB

    Novartis Pharmaceuticals

    Chronic Myelogenous Leukemia in chronic phase (CML-CP), previously treated with imatinib and have not achieved deep molecular response

    phase 2 small molecule active

    1 trial

  8. Seasonal flu vaccine

    Novartis Pharmaceuticals

    Seasonal Influenza

    phase 2 mab completed

    1 trial

  9. Selatogrel

    Viatris Pharmaceuticals Co.,

    Stable Coronary Artery Disease

    phase 2 small molecule completed

    1 trial

  10. Serelaxin

    Novartis Pharmaceuticals

    Acute Heart Failure

    phase 2 small molecule completed

    1 trial

  11. SerpinPC

    Centessa Pharmaceuticals plc

    Hemophilia B with Inhibitor

    phase 2 small molecule terminated

    1 trial

  12. Sertraline+Antibiotic (penicillin/azithromycin)

    CNS Pharmaceuticals

    Pandas

    phase 2 small molecule terminated

    1 trial

  13. Setmelanotide

    Rhythm Pharmaceuticals Netherlands B.V.

    Genetic Obesity

    phase 2 small molecule completed

    2 trials

  14. Setmelanotide

    Rhythm Pharmaceuticals Netherlands B.V.

    Overweight

    phase 2 small molecule completed

    1 trial

  15. Setmelanotide

    Rhythm Pharmaceuticals Netherlands B.V.

    Overweight and Obesity

    phase 2 small molecule completed

    1 trial

  16. Setmelanotide

    Rhythm Pharmaceuticals Netherlands B.V.

    Hypertriglyceridemia

    phase 2 small molecule completed

    1 trial

  17. Setmelanotide

    Rhythm Pharmaceuticals Netherlands B.V.

    Prader-Willi Syndrome

    phase 2 small molecule active

    2 trials

  18. Single Site Pacing

    Rhythm Pharmaceuticals Netherlands B.V.

    Acute Myocardial Infarction

    phase 2 other completed

    1 trial

  19. Single-centre, randomised, double-blind, split-face comparative design clinical trial to evaluate the efficacy and safety of the topical formulation with 4% hydroquinone and 0,025% tretinoin versus the formulation with 4% hydroquinone in patients with facial melasma

    Lacuna Pharma Pty Ltd

    facial melasma

    phase 2 other active

    1 trial

  20. Sm-EDTMP

    Jazz Pharmaceuticals Ireland Limited

    Metastatic Osteosarcoma

    phase 2 small molecule terminated

    1 trial

  21. Sodium Oxybate

    Jazz Pharmaceuticals Ireland Limited

    Schizophrenia

    phase 2 small molecule completed

    1 trial

  22. Sodium Oxybate

    Jazz Pharmaceuticals Ireland Limited

    Alternating Hemiplegia of Childhood

    phase 2 small molecule completed

    1 trial

  23. Sodium Oxybate

    Jazz Pharmaceuticals Ireland Limited

    Essential Tremor

    phase 2 small molecule completed

    1 trial

  24. Sodium chloride Fresenius Kabi 0,9% infuzní roztok, Cerebrolysin 215,2mg/ml Injekční roztok

    Lacuna Pharma Pty Ltd

    Cerebral Autosomal Dominant Arteriopathy with subcortical Infarcts and Leukoencephalopathy (CADASIL)

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β€” verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources